Skip to main
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is positioned for potential revenue growth through its TRACER gene therapy platform, which is expected to advance collaborations into clinical trials by the 2030s. The company demonstrated compelling preclinical results with its VY1706 program, achieving significant reductions in tau messenger RNA and protein levels, indicating a substantial therapeutic effect with enhanced durability and safety compared to existing treatments. Furthermore, the innovative NeuroShuttle technology reveals promising advantages in maintaining central nervous system exposure over extended periods, further contributing to a positive outlook for the company's future financial performance.

Bears say

Voyager Therapeutics Inc. is facing a negative outlook due to delays and uncertainties surrounding the clinical development of its gene therapy pipeline, particularly concerning its lead programs. The company's financial position is impacted by a limited cash runway and increasing operational costs, which could hinder further development and commercialization efforts. Additionally, the competitive landscape in the gene therapy sector, marked by substantial investment and advancements from larger biotech firms, poses a risk to Voyager's market position and future growth prospects.

Voyager Therapeutics (VYGR) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 4 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.